DDInter1321 DDInter922
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Ocrelizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib